Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Kerri A Schoedel"'
Autor:
Catherine Mills, Nancy Chen, Beatrice Setnik, Cynthia Bartlett, Naama Levy-Cooperman, Sian Ratcliffe, Kerri A. Schoedel, Megan J. Shram, Edward M. Sellers
Publikováno v:
Journal of Clinical Psychopharmacology. 40:568-578
Background Human abuse potential studies include multiple measures to assess the subjective effects of central nervous system-active drugs. In this retrospective analysis, measurement properties of commonly used measures were assessed, and factor ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05181feca4c3f624ce5c3252791eb2ae
https://doi.org/10.1097/jcp.0000000000001302
https://doi.org/10.1097/jcp.0000000000001302
Publikováno v:
Sleep. 45
Study Objectives Abuse potential properties have been reported for the dual orexin receptor antagonists (DORAs) suvorexant and lemborexant. Daridorexant is a new DORA currently in late-stage clinical development. This randomized, double-blind, double
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e36aad227cd4f79d02ddddcabe0f64e8
https://doi.org/10.1093/sleep/zsab224
https://doi.org/10.1093/sleep/zsab224
Autor:
Isabella Szeto, Marie-Henriette Eerdekens, Robert Nemeth, Elke Kleideiter, Karin Göhler, Marta Sokolowska, Kerri A. Schoedel
Publikováno v:
Journal of Clinical Psychopharmacology. 39:46-56
Background Cebranopadol is a nociceptin/orphanin FQ peptide/opioid receptor agonist with central antinociceptive activity. We hypothesize that this novel mechanism of action may lead to a lower risk of abuse compared with pure μ-opioid peptide recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759d6c94421f94c4a935bc09fd502c52
https://doi.org/10.1097/jcp.0000000000000995
https://doi.org/10.1097/jcp.0000000000000995
Publikováno v:
Psychopharmacology
Abuse and misuse of prescription drugs remains an ongoing concern in the USA and worldwide; thus, all centrally active new drugs must be assessed for abuse and dependence potential. Sphingosine-1-phosphate (S1P) receptor modulators are used primarily
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e945f3f02b07f0b77af8d91b7fb0f37a
https://pubmed.ncbi.nlm.nih.gov/34773483
https://pubmed.ncbi.nlm.nih.gov/34773483
Autor:
Kerri A. Schoedel, Tilden Etges, Beatrice Setnik, Edward M. Sellers, Isabella Szeto, Catherine Mills, Naama Levy-Cooperman, Kenneth W. Sommerville
Publikováno v:
Epilepsy & Behavior. 88:162-171
Rationale Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d525e52d88da2bf3cb143416a3c0a9dc
https://doi.org/10.1016/j.yebeh.2018.07.027
https://doi.org/10.1016/j.yebeh.2018.07.027
Autor:
Kerri A. Schoedel, Edward M. Sellers, Bijan Chakraborty, Susan L Potts, Stephen O. McMorn, Kathleen Zerbe
Publikováno v:
Journal of Opioid Management. 7:179-192
Objective: To compare the subjective effects of oxymorphone extended release (OM-ER ) versus oxycodone controlled release (OC-CR ).Design: Randomized, double-blind, crossover study.Setting: Inpatient unit.Subjects: Healthy, nondependent recreational
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::823057e7ba2f979acf012f4f27d00eaf
https://doi.org/10.5055/jom.2011.0061
https://doi.org/10.5055/jom.2011.0061
Publikováno v:
Journal of Clinical Psychopharmacology. 37:675-683
PURPOSE This phase 1, randomized, double-blind, placebo- and active comparator-controlled crossover study assessed the abuse potential of the antiepileptic drug, lacosamide. METHODS After a qualification phase, 38 healthy, recreational central nervou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::132623aa700ad8bca42375a5b1f5014f
https://doi.org/10.1097/jcp.0000000000000780
https://doi.org/10.1097/jcp.0000000000000780
Publikováno v:
European Neuropsychopharmacology. 40:S21-S22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16090c1a26a54717f01336ed2e1c0c8e
https://doi.org/10.1016/j.euroneuro.2020.09.034
https://doi.org/10.1016/j.euroneuro.2020.09.034
Autor:
John A. Wagner, Matthew D. Troyer, Xiaodong Li, Jacqueline B. McCrea, Nicole Lewis, Kerri A. Schoedel, Hong Sun, Deborah Panebianco, Naama Levy-Cooperman, Jang-Ho Cha, Wen Liu, William P. Kennedy, Edward M. Sellers, Janice Faulknor, Phung Bondiskey
Publikováno v:
Journal of Clinical Psychopharmacology. 36:314-323
Suvorexant is a dual orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia at a maximum dose of 20 mg. This randomized double-blind crossover study evaluated the abuse potential of suvorexant in 36 healthy r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3bfe7508f1cbd6a7e9ff9f3d78bc26a
https://doi.org/10.1097/jcp.0000000000000516
https://doi.org/10.1097/jcp.0000000000000516
Autor:
Kerri A. Schoedel, Megan J. Shram, Naama Levy-Cooperman, Glenn C. Pixton, Carl L. Roland, Beatrice Setnik
Publikováno v:
Journal of opioid management. 13(6)
With the development of opioid abuse-deterrent formulations (ADFs), there is a need to conduct well-designed human abuse potential studies to evaluate the effectiveness of their deterrent properties. Although these types of studies have been conducte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc787879dafa071aa4777f0348e70390
https://pubmed.ncbi.nlm.nih.gov/29308594
https://pubmed.ncbi.nlm.nih.gov/29308594